Skip to main content

Advertisement

Table 1 Characteristics of the study subjects

From: Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review

Characteristic Total cohort Subgroup*
Number of subjects (male) 333 174
Age (y), mean ± SD 68.6 ± 10.4 67.1 ± 10.9
Comorbidity, n (%) 229 (68.8) 116 (66.7)
Comorbid diseases, n (%)   
 1. Hypertension 110 (33.0) 61 (35.1)
 2. Neuropsychiatric 58 (17.4) 28 (16.1)
 3. Cardiac 52 (15.6) 20 (11.5)
 4. Endocrine/metabolic 51 (15.3) 22 (12.6)
 5. Respiratory 35 (10.5) 16 (9.2)
 6. Malignancy 23 (6.9) 12 (6.9)
 7. Chronic kidney disease 22 (6.6) 10 (5.7)
 8. Hepatobiliary 21 (6.3) 15 (8.6)
 9. Rheumatoid arthritis 17 (5.1) 14 (8.0)
Fracture history, n (%) 301 (90.4) 151 (86.8)
Fracture sites, n (%)   
 Spine 265 (79.6) 134 (77.0)
 Hip 48 (14.4) 21 (12.1)
 Others@ 21 (6.3) 8 (4.6)
Baseline DXA, n (%) 94 (28.2) 60 (34.5)
BMD T-score (SD), mean ± SEM   
 Spine −2.0 ± 0.2 −1.9 ± 0.2
 Femoral neck −2.1 ± 0.1 −1.9 ± 0.1
 Total hip −1.7 ± 0.1 −1.6 ± 0.2
First prescriber, n (%)   
 Rheumatology 140 (42.0) 85 (48.9)
 Orthopedics 101 (30.3) 37 (21.3)
 Others# 92 (27.6) 52 (29.9)
Enrolment criteria   
 NOF recommendation, n (%) 282 (84.7) 144 (82.8)
 ACR guideline, n (%) 51 (15.3) 30 (17.2)
Vertebroplasty, n (%) 11 (3.3) 6 (3.4)
Tobacco use 1 (0.3) 0 (0)
Alcohol use 2 (0.6) 1 (0.6)
  1. *Subjects with MPR ≥ 80% at year 1; NOF (2008): Clinician's Guide to Prevention and Treatment of Osteoporosis by the National Osteoporosis Foundation (2008); ACR (2001): Recommendations for the treatment and prevention of glucocorticoid-induced osteoporosis by the American College of Rheumatology (2001); DXA: Dual energy X-ray absorptiometry; BMD: bone mineral density; SD: standard deviation; SEM: standard error of the mean; Serum creatinine >1.4 mg/dl; @: including rib, wrist, upper arm and pelvis; #: Physician of Family Medicine, Metabolism, Rehabilitation.